THERM-A-LUNG: Thermotherapy Against Persistent Bacterial LUNG Infections

Sponsor
Chronic Obstructive Pulmonary Disease Trial Network, Denmark (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05351242
Collaborator
(none)
150
2
44

Study Details

Study Description

Brief Summary

The aim of this study is to determine whether an intervention with frequent thermotherapy will be able to reduce the amount of colonizing bacteria in the bronchoalveolar lavage sample and eradicate the colonizing bacteria.

Condition or Disease Intervention/Treatment Phase
  • Other: Thermotherapy/sauna bath
N/A

Detailed Description

Normally, bacterial lung infections are acute such as community-acquired pneumonia and typically resolve after antibiotic therapy without leaving much lasting damage on the lungs. However, a great amount of persons with disrupted clearance of mucus and/or lung immune system get persistent lung infections, which can be life-long, usually do not resolve even with antibiotics, and can greatly increase morbidity and mortality. IThese persistent lung infections are thus characterized by stable periods with exacerbations inbetween, akin to chronic lung diseases such as asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. In addition, it has not been thoroughly investigated whether antibiotic regimens have an effect on disease control, as biofilm formation prevents antibiotics from killing the bacteria.

This is a randomized, controlled, multi-center, superiority trial evaluating the effect of a thermotherapy intervention, consisting of min. 7 minutes stay in min. 85℃ environment at least 4 times a week for 6 months, in persons with persistent bacterial lung infection, defined as min. 2 positive cultures during the last 24 months for one of the following bacteria: Pseudomonas aeruginosa, Achromobacter xylosoxidans, Stenotrophomonas maltophilia, Klebsiella oxytoca, Klebsiella pneumoniae, Haemophilus influenzae or Staphylococcus aureus, incl. 1 positive culture after attempted eradication therapy. The aim of the study is to investigate whether thermotherapy may offer a valid proposal for treatment of chronic lung infections.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Thermotherapy Against Persistent Bacterial LUNG Infections
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Sep 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Thermotherapy/sauna bath

Must go to a sauna (min. Temperature 85℃) min. 4 times a week for 6 months. Each sauna bath must last at least 7 minutes. The intervention patients receive a subscription card for a sauna during the period. Patients will still receive pre-existing treatment

Other: Thermotherapy/sauna bath
Thermotherapy/sauna bath

No Intervention: No thermotherapy/sauna bath

Not allowed to go to a sauna for 6 months. Patients who come to do so, by e.g. an oversight, however, remain in the study, to avoid introducing bias. It will be registered as a "protocol violation", but the patient will be included in Intention To Treat analysis and modified Intention To Treat analysis. Patients will still receive pre-existing treatment.

Outcome Measures

Primary Outcome Measures

  1. Changes in bacterial growth (measured in cfu/mL) from bronchoalveolar lavage after 6 months [6 months]

  2. Eradication of the cultured bacteria at baseline, defined by no use of antibiotics the last 14 days at the follow-up assessment after 6 months [6 months]

Secondary Outcome Measures

  1. Number of hospitalizations for all causes or death within 6 months [6 months]

  2. Number of antibiotic treatment regimes within 6 months [6 months]

  3. Physical performance measured by distance walked over 6 minutes [6 months]

  4. Changes in FEV1 after 6 months [6 months]

  5. Changes in BMI after 6 months [6 months]

  6. Clinically relevant changes in Chronic Obstructive Pulmonary Disease Assessment Test-score (range from 0-40, higher is worse) after 6 months [6 months]

  7. Changes in status from Medical Research Council-dyspnea score (range from 0-5, higher is worse) from <3 to 3≥, after 6 months [6 months]

  8. Changes in composition of the lung microbiota after 6 months [6 months]

  9. Changes in abundance of the lung microbiota after 6 months [6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years

  • Competent and capable

  • FEV1>1,0 L

  • Have had a positive culture from sputum or BAL min. 2 times in the last 24 months for bacteria of the species: Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Staphylococcus aureus, Haemophilus influenzae, Achromobacter xylosoxidans, Klebsiella oxytoca or Klebsiella pneumoniae. In addition, min. 1 positive culture after treatment with antibiotics

  • Willing to go to a sauna (min. temperature of 85℃ for at least 7 minutes) four times weekly for six months or avoid going to a sauna for six months

Exclusion Criteria:
  • Allergy to lidocaine and/or midazolam

  • Contraindications to bronchoscopy

  • Previous severe laryngospasm (intubation requiring)

  • Pregnancy/breastfeeding

  • Severe linguistic problems or inability to give informed consent

  • Severe mental illness that is not controlled with medication. NB: Patients with controlled mental illness can be included and will be asked on an equal footing as others

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Chronic Obstructive Pulmonary Disease Trial Network, Denmark

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
ClinicalTrials.gov Identifier:
NCT05351242
Other Study ID Numbers:
  • THERM-A-LUNG
First Posted:
Apr 28, 2022
Last Update Posted:
Jul 7, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 7, 2022